Percutaneous Left Atrial Appendage Closure in a Patient with Diffuse Alveolar Hemorrhaging Associated with Anticoagulant Therapy and Atrial Fibrillation

Overview

Journal Intern Med

Specialty General Medicine

Date 2021 Nov 29

PMID 34840230

Authors

Takaaki Ogoshi

Masato Fukunaga

Yu Suzuki

Yusuke Taura

Kazuhiro Yatera

Affiliations

Soon will be listed here.

Abstract

Diffuse alveolar hemorrhaging (DAH) due to oral anticoagulation (OAC) is a life-threatening condition that leads to severe respiratory failure. There is a clinical dilemma in that OAC-induced DAH often forces the discontinuation of OAC therapy and the administration of high-dose corticosteroids, which increases the risk of stroke and cardiovascular events. We herein report the first case of OAC-induced DAH and atrial fibrillation (AF) in a patient who completely discontinued OAC therapy and high-dose corticosteroids after experiencing percutaneous left atrial appendage (LAA) occlusion. This case suggests that percutaneous LAA closure may aid in the management of OAC-induced DAH and AF.

References

de Prost N, Parrot A, Picard C, Ancel P, Mayaud C, Fartoukh M . Diffuse alveolar haemorrhage: factors associated with in-hospital and long-term mortality. Eur Respir J. 2009; 35(6):1303-11. DOI: 10.1183/09031936.00075309. View

Nitta K, Imamura H, Yashio A, Kashima S, Mochizuki K . Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy. Case Rep Crit Care. 2016; 2016:7938062. PMC: 5107846. DOI: 10.1155/2016/7938062. View

Reddy V, Doshi S, Sievert H, Buchbinder M, Neuzil P, Huber K . Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013; 127(6):720-9. DOI: 10.1161/CIRCULATIONAHA.112.114389. View

Quadrelli S, Dubinsky D, Solis M, Yucra D, Hernandez M, Karlen H . Immune diffuse alveolar hemorrhage: Clinical presentation and outcome. Respir Med. 2017; 129:59-62. DOI: 10.1016/j.rmed.2017.06.003. View

Franks T, Koss M . Pulmonary capillaritis. Curr Opin Pulm Med. 2000; 6(5):430-5. DOI: 10.1097/00063198-200009000-00008. View

Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P . Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020; 75(25):3122-3135. DOI: 10.1016/j.jacc.2020.04.067. View

Borjian S, Hakkak N, Amin Borjian M . A rare case of Diffuse Alveolar Hemorrhage (DAH) due to warfarin toxicity. Rom J Intern Med. 2019; 58(1):35-39. DOI: 10.2478/rjim-2019-0023. View

Aonuma K, Yamasaki H, Nakamura M, Matsumoto T, Takayama M, Ando K . Efficacy and Safety of Left Atrial Appendage Closure With WATCHMAN in Japanese Nonvalvular Atrial Fibrillation Patients　- Final 2-Year Follow-up Outcome Data From the SALUTE Trial. Circ J. 2020; 84(8):1237-1243. DOI: 10.1253/circj.CJ-20-0196. View

Waness A, Aldabbagh T, Harakati M . Diffuse alveolar haemorrhage secondary to warfarin therapy for atrial fibrillation: a case report and literature review. BMJ Case Rep. 2011; 2009. PMC: 3028302. DOI: 10.1136/bcr.08.2008.0757. View

10.

Gabrilovich M, Buxton D, Lykins D, McMillen S, Onadeko O . Diffuse alveolar hemorrhage secondary to apixaban administration. Chest. 2014; 146(3):e115-e116. DOI: 10.1378/chest.14-0651. View

11.

Lichtenberger 3rd J, Digumarthy S, Abbott G, Shepard J, Sharma A . Diffuse pulmonary hemorrhage: clues to the diagnosis. Curr Probl Diagn Radiol. 2014; 43(3):128-39. DOI: 10.1067/j.cpradiol.2014.01.002. View

12.

Erdogan D, Kocaman O, Oflaz H, Goren T . Alveolar hemorrhage associated with warfarin therapy: a case report and literature review. Int J Cardiovasc Imaging. 2004; 20(2):155-9. DOI: 10.1023/b:caim.0000014101.06445.66. View

13.

Johannesdottir S, Horvath-Puho E, Dekkers O, Cannegieter S, Jorgensen J, Ehrenstein V . Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 2013; 173(9):743-52. DOI: 10.1001/jamainternmed.2013.122. View

14.

Boersma L, Schmidt B, Betts T, Sievert H, Tamburino C, Teiger E . Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016; 37(31):2465-74. PMC: 4996118. DOI: 10.1093/eurheartj/ehv730. View

15.

Chew D, Piccini J . Postprocedural Antithrombotic Therapy Following Left Atrial Appendage Occlusion: No Longer Adrift in Uncertainty?. Circ Cardiovasc Interv. 2020; 13(7):e009534. DOI: 10.1161/CIRCINTERVENTIONS.120.009534. View

16.

Blackshear J, ODell J . Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996; 61(2):755-9. DOI: 10.1016/0003-4975(95)00887-X. View

17.

Colby T, Fukuoka J, Ewaskow S, Helmers R, Leslie K . Pathologic approach to pulmonary hemorrhage. Ann Diagn Pathol. 2001; 5(5):309-19. DOI: 10.1053/adpa.2001.27923. View

18.

Holmes D, Reddy V, Turi Z, Doshi S, Sievert H, Buchbinder M . Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374(9689):534-42. DOI: 10.1016/S0140-6736(09)61343-X. View

19.

Otoshi T, Kataoka Y, Nakagawa A, Otsuka K, Tomii K . Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort Study. Lung. 2016; 194(3):475-81. DOI: 10.1007/s00408-016-9873-4. View

20.

Kunal S, Bagarhatta R, Singh S, Sharma S . Warfarin-induced diffuse alveolar hemorrhage: Case report and a review of the literature. Lung India. 2019; 36(6):534-539. PMC: 6852223. DOI: 10.4103/lungindia.lungindia_8_19. View